What happened with FOCL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
EDAP TMS S.A. focuses on devices used by urologists, particularly for prostate cancer. Its flagship Focal One system combines imaging and robotic positioning to direct concentrated ultrasound energy at prostate tissue selected by the physician. This technology, called high-intensity focused ultrasound (HIFU), accounts for most of the company’s revenue.
Hospitals and clinics buy Focal One through EDAP’s sales teams or distributors. Some instead lease equipment or pay according to the treatments performed. Once systems are in use, EDAP earns recurring revenue from consumables and maintenance. Selling other manufacturers’ urology equipment remains a substantial business, although EDAP is shifting its investment toward HIFU. It has stopped selling new Sonolith i-move stone-treatment systems but continues supplying parts, consumables and repairs for existing equipment.
The business depends on hospitals’ equipment budgets and physicians’ willingness to adopt HIFU, which in turn depends partly on clinical evidence and reimbursement. U.S. private-insurer coverage remains limited. EDAP must obtain and maintain regulatory authorization to market its devices, and those authorizations can restrict permitted uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
EDAP's growth depends on Focal One purchases and treatment adoption, with Sonablate Corporation another HIFU rival to watch beyond this list.
Profound Medical's TULSA-PRO competes with EDAP's Focal One for purchases of equipment that uses ultrasound to destroy targeted prostate tissue, and for recurring revenue as patients receive treatment. Watch TULSA-PRO equipment sales and revenue from single-use treatment devices and related services for signs of competitive pressure on EDAP's equipment and treatment revenue.
AngioDynamics sells NanoKnife for tissue ablation using irreversible electroporation, an alternative to EDAP's Focal One ultrasound treatment, and names EDAP as a primary competitor. Its news on NanoKnife regulatory and reimbursement approvals is worth watching for competition facing Focal One; its broader sales also include cardiovascular devices, so they are not a clean measure of this rivalry.
EDAP TMS S.A. earningsThis company
EDAP TMS earns from Focal One system sales and the treatments that follow, so this report will show whether hospitals are buying the systems and patients are receiving more treatments.
Read HIFU system sales alongside treatment-driven revenue from RPPs, leases, disposables and services. If both rise, hospitals are buying systems and the installed base is generating more treatment revenue, helping replace shrinking ESWL and distribution businesses. If system sales or treatment revenue weakens, purchases or use are not yet supporting that shift.
Profound Medical Corp. earningsPROF
Profound Medical's report will show whether TULSA-PRO is gaining ground against EDAP for ultrasound equipment purchases and recurring treatment revenue in prostate care.
Watch TULSA-PRO equipment sales alongside revenue from single-use treatment devices and related services. Growth in both would show Profound Medical selling more systems and generating more follow-on treatment revenue in the same prostate-care market, putting more pressure on EDAP's Focal One sales and treatment revenue. Weakness in both would offer less evidence of competitive pressure.
